|  |  |  |
| --- | --- | --- |
| رديف | كتب رشته روانپزشكي | توضيحات |
| 1- Boland R, Verduin ML, Ruiz P. Kaplan & Sadock’s synopsis of psychiatry. 12th edition,2022.  2- Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry.10th, edition,2017 . Chapter 2-Neuropsychiatry Chapter 5- Quantitative and Experimental Methods in Psychiatry Chapter 12- Schizophrenia and Other Psychotic Disorders Chapter 13- Mood Disorders Chapter 14- Anxiety Disorders Chapter 15- OCD and Related Disorders Chapter 17- PTSD Chapter 27- Psychosomatic Medicine 3- Tasman A, Kay J, Lieberman JA, First MB, Riba MB. Psychiatry. 4th edition. 2015. Chapter1- Listening to the patient (Pages 3-19) Chapter 5- Professional ethics and Boundaries (Pages 71-84) 4- Beck JS, Cognitive Behavior Therapy. 3th edition. 2021. -۵چکيده بارگذاری شده خلاصه روان پزشکی قانونی در سايت sanjeshp.ir -۶منشور اخلاق حرفه ای روانپزشکی در ايران، ويراست اول ، .١٣٩۴مصوب مجمع عمومی انجمن علمی روانپزشکان ايران که در سايت انجمن در دسترس می باشد. -٧شناسنامه و استاندارد خدمت تحريک مغناطيسی مغزی فراجمجمه ای ی مکرر )آر تی ام اس( زمستان .١٣٩٩ دبيرخانه شورای راهبردی تدوين راهنماهای سلامت- معاونت درمان- وزارت بهداشت ، درمان و آموزش پزشکی -٨راهنمای بالينی مديريت اختلال دو قطبی بزرگسالان ايران ) درمان های دارويی و ابزاری(. زمستان .١٣٩٩ دبيرخانه شورای راهبردی تدوين راهنماهای بالينی- معاونت درمان- وزارت بهداشت، درمان . آموزش پزشکی -٩**مجموعه ۵٠مقاله منتخب روانپزشکی که به شرح زير اعلام می گردد**. 1 Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World psychiatry. 2022;21(2):295-307. 2. Lu Z, Sun Y, Zhang Y, Chen Y, Guo L, Liao Y, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.Translational psychiatry. 2022;12(1):1-14. 3. Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum | : كتب | ٢٠ |
| disorders: an individual participant data meta-analysis. The Lancet Psychiatry. 2020;7(9):749-61. 4. Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World psychiatry. 2022;21(2):248-71. 5. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet.2019;394(10202):939-51. 6. Bighelli I, Rodolico A, García-Mieres H, Pitschel-Walz G, Hansen W-P, Schneider-Thoma J, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. The Lancet Psychiatry. 2021;8(11):969-80. 7. Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, et al. Cannabis use and psychosis: a review of reviews. European archives of psychiatry and clinical neuroscience.2020;270(4):403-12. 8. Sharma V, Sharma P, Sharma S. Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice. Expert review of neurotherapeutics.2020;20(4):373-83. 9. Schiweck C, Arteaga-Henriquez G, Aichholzer M, Thanarajah SE, Vargas-Cáceres S, Matura S, et al. Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2021;124:100-23. 10. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar disorders. 2018;20(2):97-170. 11. Excellence NIfC. Depression in adults: treatment and management. NICE Guideline: Short Version Draft for Second Consultation. 2018. 12. Pearce M, Garcia L, Abbas A, Strain T, Schuch FB, Golubic R, et al. Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis. JAMA psychiatry. 2022. 13. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular psychiatry. 2022:1-14. 14. Miller JN, Black DW. Bipolar disorder and suicide: a review. Current psychiatry reports.2020;22(2):1-10. 15. Trisha C, Kamyar K, Yatham LN. Treatment of Mixed Features in Bipolar Disorder: an Updated View. Current Psychiatry Reports. 2020;22(3). 16. Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Frontiers in psychiatry. 2020:1412. 17. Sharma E, Sharma LP, Balachander S, Lin B, Manohar H, Khanna P, et al. Comorbidities in Obsessive-Compulsive Disorder Across the Lifespan: A Systematic Review and Meta-Analysis. Frontiers inpsychiatry. 2021;12. 18. Kayser RR. Pharmacotherapy for treatment-resistant obsessive-compulsive disorder. The Journal of clinical psychiatry. 2020;81(5):14428. 19. Rasmussen AR, Parnas J. What is obsession? Differentiating obsessive-compulsive disorder and the schizophrenia spectrum. Schizophrenia Research. 2022;243:1-8. 20. Huang Z-D, Zhao Y-F, Li S, Gu H-Y, Lin L-L, Yang Z-Y, et al. Comparative efficacy and acceptability |
| of pharmaceutical management for adults with post-traumatic stress disorder: A systematic review and meta-analysis. Frontiers in pharmacology. 2020;11:559. 21. Collaborators GMD. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry. 2022;9(2):137-50. 22. Wagner-Skacel J, Matzer F, Kohlhammer-Dohr A, Dalkner N, Jauk E. Assessment of personality functioning in psychosomatic medicine. Wiener klinische Wochenschrift. 2022:1-9. 23. Aybek S, Perez DL. Diagnosis and management of functional neurological disorder. bmj.2022;376. 24. Gilmour GS, Nielsen G, Teodoro T, Yogarajah M, Coebergh JA, Dilley MD, et al. Management of functional neurological disorder. Journal of Neurology. 2020;267(7):2164-72. 25. Hausteiner-Wiehle C, Hungerer S. Factitious disorders in everyday clinical practice. Deutsches Ärzteblatt International. 2020;117(26):452. 26. UK NGC. Attention deficit hyperactivity disorder: diagnosis and management. 2018. 27. Resmark G, Herpertz S, Herpertz-Dahlmann B, Zeeck A. Treatment of anorexia nervosa—new evidence-based guidelines. Journal of clinical medicine. 2019;8(2):153. 28. Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. Bmj. 2019;367. 29. Magierski R, Sobow T, Schwertner E, Religa D. Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress. Front Pharmacol [Internet]. 2020 Jul 31 11. 30. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-46. 31. Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. Journal of Alzheimer's disease. 2019;67(3):779-94. 32. Fe'li SN, Ardekani SMY, Fallahzadeh H, Dehghani A. Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics. Medical Journal of the Islamic Republic of Iran. 2019;33:97. 33. Lisoway AJ, Chen CC, Zai CC, Tiwari AK, Kennedy JL. Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. Schizophrenia Research. 2021;232:112-24. 34. Gowda GS, Isaac MK. Models of Care of Schizophrenia in the Community—An International Perspective. Current psychiatry reports. 2022:1-8. 35. Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. Iranian Journal of Psychiatry. 2022;17(3):320-40. 36. Mas M, García-Vicente JA, Estrada-Gelonch A, Pérez-Mañá C, Papaseit E, Torrens M, et al. Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence. Journal of ClinicalMedicine. 2022;11(14):4038. 37. Lewis C, Roberts NP, Andrew M, Starling E, Bisson JI. Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis. European journal of psychotraumatology.2020;11(1):1729633. 38. Bonde JPE, Jensen JH, Smid GE, Flachs EM, Elklit A, Mors O, et al. Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review. Acta Psychiatrica Scandinavica. 2022;145(2):116-31. |
| 39. Jelinek L, Voderholzer U, Moritz S, Carsten HP, Riesel A, Miegel F. When a nightmare comes true: Change in obsessive-compulsive disorder over the first months of the COVID-19 pandemic. Journal of anxiety disorders. 2021;84:102493. 40. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. bmj. 2022;376. 41. Nezgovorova V, Reid J, Fineberg N, Hollander E. Optimizing first line treatments for adults with OCD. Comprehensive Psychiatry. 2022:152305. 42. Mehta R, Giri S, Mallick BN. REM sleep loss–induced elevated noradrenaline could predispose an individual to psychosomatic disorders: a review focused on proposal for prediction, prevention, and personalized treatment. EPMA Journal. 2020;11(4):529-49. 43. Enck P, Klosterhalfen S. Placebo responses and placebo effects in functional gastrointestinal disorders. Frontiers in Psychiatry. 2020;11:797. 44. Masoomi M, Gholamian F, Sharifi V, Shadloo B. Self-immolation among women in Iran: A narrative review. Iranian Journal of Psychiatry and Behavioral Sciences. 2020;14(4). 45. Shahini N, Talaei A, Salimi Z, Adinepour Sarab M, Gholamzad S, Teimouri A, et al. Temperament and character traits in substance use disorder in Iran: a case control study. BMC psychology.2021;9(1):1-8. 46. van Oostveen WM, de Lange EC. Imaging techniques in Alzheimer’s disease: a review of applications in early diagnosis and longitudinal monitoring. International journal of molecular sciences.021;22(4):2110. 47. Pressman PS, Matlock D, Ducharme S. Distinguishing Behavioral Variant Frontotemporal Dementia from primary psychiatric disorders: A review of recently published consensus recommendations from the Neuropsychiatric International Consortium for Frontotemporal Dementia. The Journal of Neuropsychiatry and Clinical Neurosciences. 2021;33(2):152-6. 48. Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry. 2022. 49. Jobehdar MM, Razaghi E, Haghdoost AA, Baleshzar A, Khoshnood K, Ghasemzadeh MR, et al. Factors That Influence the Effectiveness of Primary Prevention of Substance Use: A Review of Reviews. Iranian Journal of Psychiatry and Behavioral Sciences. 2021;15(4). 50. Reynolds 3rd CF, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry. 2022;21(3):336-63 |

**توضيح** : در صورت وجود تناقض در مطالب ، منبع جديدتر مورد استناد مي باشد.  
با توجه به اهميت مهارت باليني داوطلبان آزمون دانشنامه تخصصي رشته روانپزشكي، علاوه بر استفاده از روش ،OSCEاز روش mini-CEXنيز استفاده خواهد شد